Chemotherapy At Home Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The chemotherapy at home services market size is expected to grow from USD 1.68 billion in 2025 to USD 1.79 billion in 2026 and is forecast to reach USD 2.59 billion by 2031 at 7.64% CAGR over 2026-2031. This report is Segmented by Product (Chemotherapy Drugs, Chemotherapy Infusion Pumps), Route of Administration (Oral, Intravenous), Cancer Type (Breast Cancer, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other Cancer Types), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Chemotherapy At Home Services Market Trends and Insights

Rising Cancer Incidence and Treatment Volumes

The chemotherapy at home services market is gaining a larger patient base because global cancer volumes remain high and are still increasing. The World Health Organization reported 20 million new cancer cases and 9.7 million deaths in 2022, and it expects annual new cases to rise above 35 million by 2050. This rise matters for home-based care because hospital infusion capacity does not expand as quickly as case volumes in many health systems. The same pressure is being amplified by the large survivorship pool, with 53.5 million people alive within 5 years of a cancer diagnosis as of 2022. Many of these patients remain on adjuvant, maintenance, or repeat-cycle treatment plans that fit recurring home service models. That gives the chemotherapy at home services market a steady demand base that is not tied only to new diagnoses in a single year.

Preference Shift From Facility-Based Care to Home-Based Oncology Delivery

The chemotherapy at home services market is moving forward as providers, patients, and payers become more comfortable with treatment outside the hospital. Mayo Clinic’s Cancer CARE Beyond Walls program reported 93 home intravenous chemotherapy infusions with no infusion reactions and no catheter-related infections, which supports confidence in care quality and delivery safety. The economic case is also strong, as UnitedHealth Group estimated that shifting cancer drug administration from hospital outpatient settings to home or physician office settings can reduce costs by 32%-39% per commercially insured patient. The same analysis estimated USD 12 billion in annual savings if the hospital infusion share drops from 60% to 30%. Those savings are encouraging payers to favor lower-cost settings more actively than before. As a result, the chemotherapy at home services market is being shaped not only by patient convenience, but also by deliberate site-of-care redirection.

Oncology Nurse and Pharmacist Capacity Gaps

The chemotherapy at home services market faces a basic supply problem because oncology-trained nurses and pharmacists remain hard to recruit and retain. The Lancet Oncology Commission identified the global cancer workforce as a critical resource gap and linked care quality directly to staffing levels across countries and care settings. Home administration adds another layer of difficulty because general home health capabilities are not always enough for chemotherapy toxicity assessment and rapid response. Staff must distinguish treatment side effects from disease progression and make correct escalation decisions during visits or remote review. That raises training needs well above standard infusion support in lower-acuity services. Until that workforce base deepens, the chemotherapy at home services market will continue to expand more slowly than patient demand would otherwise allow.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Remote Monitoring and Tele-Oncology Support Models
• Home Infusion Logistics and Nurse Dispatch Networks Improving Treatment Feasibility
• Reimbursement Variability and Payer Authorization Friction

Segment Analysis

Chemotherapy drugs held 61.31% of revenue in 2025 in the chemotherapy at home services market, which kept the revenue profile centered on drug spending rather than equipment or logistics fees. That position reflects how most patient episodes are still built around the therapy itself, with devices and home support layered around it. Multi-day intravenous regimens such as fluorouracil-based treatment for colorectal cancer reinforce this structure because the drug and the delivery setup are used together in a single care cycle. The pump segment is still the fastest-growing product category, with an 8.36% CAGR projected through 2031. That growth is coming from broader use cases rather than from a decline in drug importance. The chemotherapy at home services industry still depends on drugs as the primary billing driver, but devices are becoming more important for enabling a larger share of those therapies to move out of clinics.

Pump adoption is rising because product formats are widening, and providers can choose between lower-cost elastomeric systems and more connected smart platforms. Fresenius described its Ivenix smart infusion platform as a meaningful growth driver for 2026, and it highlighted advanced connectivity and a 97% drug library compliance rate in its investor communication. KORU Medical also moved to widen home eligibility when it submitted a 510(k) notification in January 2026 for the FreedomEDGE infusion system to administer pertuzumab, trastuzumab, and hyaluronidase subcutaneously at home for HER2-positive breast cancer. Medicare coverage support also improved, as the CMS LCD revision effective January 25, 2026 confirmed home coverage for ambulatory infusion pumps used with continuous antineoplastic drugs including fluorouracil, cytarabine, and vincristine. These changes are pushing the chemotherapy at home services market toward a larger installed pump base without changing the central role of chemotherapy drugs in total revenue.

Complete Report Scope:

• By Product
  • Chemotherapy Drugs
  • Chemotherapy Infusion Pumps
• By Route of Administration
  • Oral
  • Intravenous
• By Cancer Type
  • Breast Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Other Cancer Types
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 45.64% of revenue in 2025 in the chemotherapy at home services market, and that lead rests on a combination of scale operators, payer support, and value-based oncology policy. Option Care Health reported more than 190 locations, more than 5,000 clinicians, and service across all 50 U.S. states, which illustrates the network depth available in the region. CMS also strengthened the operating backdrop through the Enhancing Oncology Model, which increased Monthly Enhanced Oncology Services payments and supported more patient-centered oncology workflows. The chemotherapy at home services market share in North America is also supported by stronger administrative ability to manage authorization, compounding, dispatch, and compliance at scale.

Europe remains the second-largest regional cluster in the chemotherapy at home services market, but growth is less uniform than in North America. Progress is strongest where hospital oncology teams, homecare providers, and public payment systems already work through linked operating pathways. At the same time, a peer-reviewed Belgian study showed that oncology treatment at home can cost more than standard hospital care when reimbursement is not designed to cover operating reality. That gap slows expansion because clinical feasibility alone does not guarantee provider investment or routine program scale.

Asia-Pacific is forecast to grow at a 9.59% CAGR through 2031 in the chemotherapy at home services market, making it the fastest-growing regional block. The region has a large untreated opportunity because cancer volumes are high and hospital capacity remains uneven across urban and non-urban settings. Growth is strongest where digital coordination, urban nurse availability, and payer openness are improving at the same time. South Korea and Australia already have established home infusion provider networks, while other countries are moving through earlier stages of structured oncology-at-home development. South America and the Middle East and Africa remain smaller in revenue terms, but the chemotherapy at home services market is gaining relevance there as health systems search for more flexible ways to deliver treatment outside major hospitals.

List of Companies Covered in this Report:

• Accredo Health Group, Inc.
• Advocate Health Care
• Amedisys
• Amerita, Inc.
• Amgen
• B. Braun
• Baxter
• Beckton Dickinson
• BioScrip, Inc.
• CareCentrix
• CVS Health
• Fresenius
• HealthCare atHOME
• ICU Medical
• InfiuSystem Holdings Inc.
• Jivika Healthcare
• Lincare Holdings
• LloydsPharmacy Clinical Homecare
• Medibank
• Medtronic
• Optum
• Option Care Health, Inc.
• Penn Medicine
• Portea Medical Private Limited
• Sciensus Pharma Services Limited
• TCP Homecare
• Ubiqare Health Pvt. Ltd.
• View Health Pty Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support